9th Annual Vaccine World Summit 2019
Our Contribution
During the conference, Viroclinics Biosciences’ experts will shed light on the topic: “Animal models to evaluate countermeasures against Influenza viruses”, during our presentation slot on February 13th.
The ongoing emergence of influenza viruses in humans and animals, through mechanisms of antigenic drift, shift and interspecies transmission, calls for the use of animal models that can rapidly address pathogenesis and transmission characteristics of influenza, as well as evaluate preventive and therapeutic intervention strategies.
Several animal models for influenza are currently available, including mice, guinea pigs, ferrets, cats, pigs and non-human primates. All animal models have their intrinsic pros and cons, and the research question addressed therefore basically determines the choice of the animal model.
More than one animal model may be used for the evaluation of intervention strategies for influenza. Commonly, novel generations of vaccines and antiviral strategies are tested for safety and efficacy in rodents, ferrets or macaques. The advantages and limitations of each of the available animal models, especially in the light of developing the highly desirable universal influenza vaccines, will be highlighted in this overview.
Furthermore, we will present our views on how R&D outsourcing can stimulate the innovation processes for vaccine developers. Practical case examples will be discussed and new horizons will be explored by sharing our latest insights on Influenza, and other viral targets.
We are looking forward to sharing our latest insights with you during the 9th Annual Vaccine World Summit 2019.
Speaker
Dr Koert Stittelaar, Director Preclinical Services
Dr Koert Stittelaar joined Viroclinics Biosciences in 2006. Previous to this he was a Postdoc at the Virology Department at Erasmus MC Rotterdam in vaccine and pathogenesis research projects including HIV, dengue and poxvirus preclinical research. Koert was trained in medical microbiology at the National Institute of Public Health and University of Utrecht working on Neisseria meningitidis-specific T cell responses. Koert defended his PhD thesis in 2001: “Vaccination against Measles” at the Erasmus University Rotterdam. His start at Viroclinics Biosciences boosted the Preclinical Service activities within the company. He gained expertise in the field of influenza virus and RSV intervention strategy research and is now mainly concerned with containment of highly pathogenic viruses, model development and project acquisition like polio virus related projects. Koert has authored many publications.
Contact Speaker
This form is currently undergoing maintenance. Please try again later.
OUR LATEST NEWS
Launching our new business unit Viroclinics Xellerate
Viroclinics-DDL, today announced the launch of Viroclinics Xellerate, a newly formed Business Unit focused on clinical trial support and global logistics services.
REPROCELL and VIROCLINICS-DDL Renew Collaboration Agreement in Clinical Research
Rotterdam, the Netherlands, VIROCLINICS-DDL is pleased to announce the signing of a renewal for collaboration agreement with REPROCELL. REPROCELL will provide sample processing services to VIROCLINICS-DDL to support several clinical research projects.
ENPICOM and Viroclinics-DDL receive joint MIT R&D ZH subsidy subsidy to accelerate and improve antibody and vaccine discovery and development
Partnership combines Viroclinics-DDL’s diagnostic and high-throughput sequencing experience with ENPICOM’s expertise in bioinformatics and immunomics.
